

HR 3

Elijah E. Cummings Lower Drug Costs Now Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 19, 2019

Current Status: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

Latest Action: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
(Sep 8, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3>

Sponsor

Name: Rep. Pallone, Frank, Jr. [D-NJ-6]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (106 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Neal, Richard E. [D-MA-1]	D · MA		Sep 19, 2019
Rep. Scott, Robert C. "Bobby" [D-VA-3]	D · VA		Sep 19, 2019
Rep. Larson, John B. [D-CT-1]	D · CT		Sep 20, 2019
Del. Sablan, Gregorio Kilili Camacho [D-MP-At Large]	D · MP		Sep 24, 2019
Rep. Case, Ed [D-HI-1]	D · HI		Sep 24, 2019
Rep. DeGette, Diana [D-CO-1]	D · CO		Sep 24, 2019
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Sep 24, 2019
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Sep 24, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Sep 24, 2019
Rep. Ryan, Tim [D-OH-13]	D · OH		Sep 24, 2019
Rep. Shalala, Donna E. [D-FL-27]	D · FL		Sep 24, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Sep 25, 2019
Rep. Castor, Kathy [D-FL-14]	D · FL		Sep 25, 2019
Rep. Courtney, Joe [D-CT-2]	D · CT		Sep 25, 2019
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Sep 25, 2019
Rep. Evans, Dwight [D-PA-3]	D · PA		Sep 25, 2019
Rep. Frankel, Lois [D-FL-21]	D · FL		Sep 25, 2019
Rep. Kildee, Daniel T. [D-MI-5]	D · MI		Sep 25, 2019
Rep. McGovern, James P. [D-MA-2]	D · MA		Sep 25, 2019
Rep. Moore, Gwen [D-WI-4]	D · WI		Sep 25, 2019
Rep. Norcross, Donald [D-NJ-1]	D · NJ		Sep 25, 2019
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Sep 26, 2019
Rep. Carbajal, Salud O. [D-CA-24]	D · CA		Sep 26, 2019
Rep. Hill, Katie [D-CA-25]	D · CA		Sep 26, 2019
Rep. Pappas, Chris [D-NH-1]	D · NH		Sep 26, 2019
Rep. Visclosky, Peter J. [D-IN-1]	D · IN		Sep 26, 2019
Rep. Allred, Colin Z. [D-TX-32]	D · TX		Oct 1, 2019
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Oct 1, 2019
Rep. Cartwright, Matt [D-PA-8]	D · PA		Oct 1, 2019
Rep. Cohen, Steve [D-TN-9]	D · TN		Oct 1, 2019
Rep. Hayes, Jahana [D-CT-5]	D · CT		Oct 1, 2019
Rep. Kim, Andy [D-NJ-3]	D · NJ		Oct 1, 2019
Rep. McNerney, Jerry [D-CA-9]	D · CA		Oct 1, 2019
Rep. Meng, Grace [D-NY-6]	D · NY		Oct 1, 2019
Rep. Rose, Max [D-NY-11]	D · NY		Oct 1, 2019
Rep. Thompson, Mike [D-CA-5]	D · CA		Oct 1, 2019
Rep. Trone, David J. [D-MD-6]	D · MD		Oct 1, 2019
Rep. Beatty, Joyce [D-OH-3]	D · OH		Oct 8, 2019
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Oct 8, 2019
Rep. Horsford, Steven [D-NV-4]	D · NV		Oct 8, 2019
Rep. Soto, Darren [D-FL-9]	D · FL		Oct 8, 2019

Cosponsor	Party / State	Role	Date Joined
Rep. Suozzi, Thomas R. [D-NY-3]	D · NY		Oct 8, 2019
Rep. Vela, Filemon [D-TX-34]	D · TX		Oct 8, 2019
Rep. Wild, Susan [D-PA-7]	D · PA		Oct 8, 2019
Rep. Craig, Angie [D-MN-2]	D · MN		Oct 11, 2019
Rep. Golden, Jared F. [D-ME-2]	D · ME		Oct 11, 2019
Rep. Keating, William R. [D-MA-9]	D · MA		Oct 11, 2019
Rep. Schiff, Adam B. [D-CA-28]	D · CA		Oct 11, 2019
Rep. Wasserman Schultz, Debbie [D-FL-23]	D · FL		Oct 11, 2019
Rep. Davis, Danny K. [D-IL-7]	D · IL		Oct 16, 2019
Rep. Doyle, Michael F. [D-PA-18]	D · PA		Oct 16, 2019
Rep. Garcia, Sylvia R. [D-TX-29]	D · TX		Oct 16, 2019
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Oct 16, 2019
Rep. Ruiz, Raul [D-CA-36]	D · CA		Oct 16, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Oct 16, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Oct 16, 2019
Rep. Wilson, Frederica S. [D-FL-24]	D · FL		Oct 16, 2019
Rep. Bustos, Cheri [D-IL-17]	D · IL		Oct 21, 2019
Rep. Casten, Sean [D-IL-6]	D · IL		Oct 21, 2019
Rep. Crist, Charlie [D-FL-13]	D · FL		Oct 21, 2019
Rep. Cuellar, Henry [D-TX-28]	D · TX		Oct 21, 2019
Rep. Loebsack, David [D-IA-2]	D · IA		Oct 21, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		Oct 21, 2019
Rep. Schrier, Kim [D-WA-8]	D · WA		Oct 21, 2019
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Oct 22, 2019
Rep. Sarbanes, John P. [D-MD-3]	D · MD		Oct 22, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Oct 22, 2019
Rep. Wexton, Jennifer [D-VA-10]	D · VA		Oct 22, 2019
Rep. Lawson, Al, Jr. [D-FL-5]	D · FL		Oct 28, 2019
Rep. Maloney, Sean Patrick [D-NY-18]	D · NY		Oct 28, 2019
Rep. Phillips, Dean [D-MN-3]	D · MN		Oct 28, 2019
Rep. Schneider, Bradley Scott [D-IL-10]	D · IL		Oct 28, 2019
Rep. Espaillat, Adriano [D-NY-13]	D · NY		Oct 29, 2019
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Oct 29, 2019
Rep. Meeks, Gregory W. [D-NY-5]	D · NY		Oct 29, 2019
Rep. Higgins, Brian [D-NY-26]	D · NY		Oct 30, 2019
Rep. Langevin, James R. [D-RI-2]	D · RI		Oct 30, 2019
Rep. Chu, Judy [D-CA-27]	D · CA		Oct 31, 2019
Rep. Davids, Sharice [D-KS-3]	D · KS		Oct 31, 2019
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Oct 31, 2019
Rep. Stevens, Haley M. [D-MI-11]	D · MI		Oct 31, 2019
Rep. Axne, Cynthia [D-IA-3]	D · IA		Nov 1, 2019
Rep. Beyer, Donald S., Jr. [D-VA-8]	D · VA		Nov 1, 2019

Cosponsor	Party / State	Role	Date Joined
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Nov 1, 2019
Rep. Lowey, Nita M. [D-NY-17]	D · NY		Nov 1, 2019
Rep. McEachin, A. Donald [D-VA-4]	D · VA		Nov 5, 2019
Rep. Deutch, Theodore E. [D-FL-22]	D · FL		Nov 8, 2019
Rep. Jeffries, Hakeem S. [D-NY-8]	D · NY		Nov 8, 2019
Rep. McBath, Lucy [D-GA-6]	D · GA		Nov 8, 2019
Rep. Payne, Donald M., Jr. [D-NJ-10]	D · NJ		Nov 8, 2019
Rep. Scanlon, Mary Gay [D-PA-5]	D · PA		Nov 8, 2019
Rep. Spanberger, Abigail Davis [D-VA-7]	D · VA		Nov 8, 2019
Rep. Torres, Norma J. [D-CA-35]	D · CA		Nov 8, 2019
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Nov 8, 2019
Rep. Dingell, Debbie [D-MI-12]	D · MI		Nov 12, 2019
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Nov 12, 2019
Rep. Garamendi, John [D-CA-3]	D · CA		Nov 13, 2019
Rep. McCollum, Betty [D-MN-4]	D · MN		Nov 13, 2019
Rep. Veasey, Marc A. [D-TX-33]	D · TX		Nov 13, 2019
Rep. Bass, Karen [D-CA-37]	D · CA		Nov 21, 2019
Rep. Castro, Joaquin [D-TX-20]	D · TX		Nov 21, 2019
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Nov 21, 2019
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Nov 26, 2019
Rep. Smith, Adam [D-WA-9]	D · WA		Dec 3, 2019
Rep. Lowenthal, Alan S. [D-CA-47]	D · CA		Dec 5, 2019
Rep. Fletcher, Lizzie [D-TX-7]	D · TX		Dec 6, 2019

Committee Activity

Committee	Chamber	Activity	Date
Education and Workforce Committee	House	Reported By	Dec 9, 2019
Energy and Commerce Committee	House	Discharged from	Oct 17, 2019
Ways and Means Committee	House	Referred to	Sep 19, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3376	Related bill	Mar 3, 2020: Read twice and referred to the Committee on Finance.
116 HR 5688	Related bill	Jan 28, 2020: Referred to the House Committee on Energy and Commerce.
116 HR 4618	Related bill	Jan 24, 2020: Placed on the Union Calendar, Calendar No. 302.
116 HR 4650	Related bill	Jan 24, 2020: Placed on the Union Calendar, Calendar No. 303.
116 HR 4665	Related bill	Jan 24, 2020: Placed on the Union Calendar, Calendar No. 304.
116 HRES 758	Related bill	Dec 11, 2019: Mr. Nadler moved to table the motion to reconsider
116 HR 5357	Related bill	Dec 9, 2019: Referred to the Subcommittee on Health.
116 HR 5281	Related bill	Dec 4, 2019: Referred to the Subcommittee on Health.
116 HR 4649	Related bill	Oct 30, 2019: Sponsor introductory remarks on measure. (CR H8607)
116 HR 3398	Related bill	Oct 29, 2019: Placed on the Union Calendar, Calendar No. 211.
116 HR 4835	Related bill	Oct 23, 2019: Referred to the House Committee on Education and Labor.
116 HR 4768	Related bill	Oct 22, 2019: Referred to the Subcommittee on Health.
116 HR 4629	Related bill	Oct 18, 2019: Sponsor introductory remarks on measure. (CR H8232)
116 HR 4661	Related bill	Oct 17, 2019: Sponsor introductory remarks on measure. (CR H8207)
116 HR 4675	Related bill	Oct 16, 2019: Referred to the Subcommittee on Health.
116 HR 4676	Related bill	Oct 16, 2019: Referred to the Subcommittee on Health.
116 HR 4633	Related bill	Oct 14, 2019: Referred to the Subcommittee on Health.
116 HR 4663	Related bill	Oct 14, 2019: Referred to the Subcommittee on Health.
116 HR 4666	Related bill	Oct 14, 2019: Referred to the Subcommittee on Health.
116 HR 4669	Related bill	Oct 14, 2019: Referred to the Subcommittee on Health.
116 HR 4619	Related bill	Oct 9, 2019: Referred to the Subcommittee on Health.
116 HR 2296	Related bill	Sep 24, 2019: Placed on the Union Calendar, Calendar No. 170.
116 HR 4455	Related bill	Sep 23, 2019: Referred to the Subcommittee on Health.
116 HR 3343	Related bill	Jun 19, 2019: Referred to the House Committee on Ways and Means.
116 HR 3347	Related bill	Jun 19, 2019: Referred to the House Committee on Ways and Means.
116 S 1260	Related bill	May 1, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Elijah E. Cummings Lower Drug Costs Now Act

This bill establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health.

TITLE I--LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION

The bill requires the Department of Health and Human Services (HHS) to negotiate prices for certain drugs. (Under current law, HHS may not negotiate the prices of covered drugs under the Medicare prescription drug benefit.)

Specifically, HHS must negotiate maximum prices for (1) insulin products; (2) with respect to 2023, at least 25 single-source, brand-name drugs that do not have generic competition and that are among either the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest spending under the Medicare prescription drug benefit and Medicare Advantage (MA); (3) beginning in 2024, at least 50 such single-source, brand-name drugs; and (4) newly approved single-source, brand-name drugs that meet or exceed a specified price threshold and that HHS determines are likely to meet the spending criteria. The negotiated prices must be offered under Medicare and MA and may also be offered under private health insurance unless the insurer opts out.

The negotiated maximum price may not exceed (1) 120% of the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom; or (2) if such information is not available, 85% of the U.S. average manufacturer price. Drug manufacturers that fail to comply with the bill's negotiation requirements are subject to civil and tax penalties.

TITLE II--MEDICARE PARTS B AND D PRESCRIPTION DRUG INFLATION REBATES

The bill also requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for covered drugs under Medicare that cost \$100 or more and for which the average manufacturer price increases faster than inflation.

TITLE III--PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE BENEFICIARIES

The bill reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit. Additionally, prescription drug plan sponsors must allow certain beneficiaries to make coinsurance payments in periodic installments, in accordance with CMS requirements.

TITLE IV--DRUG PRICE TRANSPARENCY

Drug manufacturers must report, subject to civil penalties, specified information for certain drugs that cost \$100 or more and that are covered under Medicare or Medicaid, based on the rate of price or spending increases. Among other things, manufacturers must report a qualifying price increase at least 30 days before the effective date of the increase; HHS must publish the information on its website the day the increase takes effect.

TITLE V--PROGRAM IMPROVEMENTS FOR MEDICARE LOW-INCOME BENEFICIARIES

The bill expands eligibility for certain premium and cost-sharing subsidies for low-income beneficiaries under the Medicare prescription drug benefit. For example, the bill (1) raises the maximum allowable income for beneficiaries to qualify, and (2) allows certain residents of U.S. territories to automatically qualify.

TITLE VI--PROVIDING FOR DENTAL, VISION, AND HEARING COVERAGE UNDER THE MEDICARE PROGRAM

The bill also expands Medicare coverage to include (1) dentures and dental and oral health services, including basic and major treatments (as determined by the CMS) as well as specified preventive and screening services; (2) hearing aids and hearing rehabilitation and treatment services; and (3) eyeglasses, contact lenses, and vision services, including routine eye examinations and contact lens fittings.

TITLE VII--NIH, FDA, AND OPIOIDS FUNDING

The bill provides additional funds for several public health programs. Among other things, the bill (1) provides specified funds for innovation projects at the National Institutes of Health through FY2030 and for innovation projects at the Food and Drug Administration through FY2029; and (2) establishes the Opioid Epidemic Response Fund to support HHS programs and initiatives, including the State Opioid Response Grant Program.

Additionally, HHS must take a series of actions relating to health care administrative costs. Specifically, HHS must develop a strategy and take associated action to reduce unnecessary costs and administrative burdens in the health care system, including Medicare, Medicaid, and the private health-insurance market, by at least half over a period of 10 years. HHS must also award grants so that states may establish commissions targeting such costs.

TITLE VIII--MISCELLANEOUS

The bill also establishes and revises several other health care programs and requirements.

For example, the bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health-insurance policies); (2) provides specified funds for the Community Health Centers Fund through FY2025; (3) establishes grant programs to support mental health and trauma services in schools, as well as career development programs for health professionals; and (4) requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid.

Additionally, the CMS must issue regulations that require direct-to-consumer television advertisements for all covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment. (On May 10, 2019, the CMS issued a final rule titled *Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency*. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least \$35 per month. The rule was scheduled to take effect July 9, 2019; however, a federal court blocked implementation, citing a lack of statutory authority.)

Actions Timeline

- **Sep 8, 2020:** Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
- **Aug 13, 2020:** Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
- **Dec 16, 2019:** Received in the Senate.
- **Dec 12, 2019:** Considered as unfinished business. (consideration: CR H10129-10225; text: CR H10141-10167)
- **Dec 12, 2019:** The House resolved into Committee of the Whole House on the state of the Union for further consideration.
- **Dec 12, 2019:** GENERAL DEBATE - The Committee of the Whole proceeded with one hour of further debate on H.R. 3.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H.Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Walden amendment No. 1.
- **Dec 12, 2019:** POSTPONED PROCEEDINGS - At the conclusion of debate on the Walden amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the noes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Tonko amendment No. 2.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Peters amendment No. 3.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 4.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the O'Halleran amendment No. 5.
- **Dec 12, 2019:** POSTPONED PROCEEDINGS - At the conclusion of debate on the O'Halleran amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. O'Halleran demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 6.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Gottheimer amendment No. 7.
- **Dec 12, 2019:** POSTPONED PROCEEDINGS - At the conclusion of debate on the Gottheimer amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Gottheimer demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Axne amendment No. 8.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Finkenauer amendment No. 9.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Luria amendment No. 10.
- **Dec 12, 2019:** POSTPONED PROCEEDINGS - At the conclusion of debate on the Luria amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Cunningham amendment No. 11.
- **Dec 12, 2019:** POSTPONED PROCEEDINGS - At the conclusion of debate on the Cunningham amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Roe (TN) demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
- **Dec 12, 2019:** DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Houlahan amendment No. 12.
- **Dec 12, 2019:** UNFINISHED BUSINESS - The Chair announced that the unfinished business was on adoption of amendments, which were debated earlier and on which further proceedings had been postponed.
- **Dec 12, 2019:** The House rose from the Committee of the Whole House on the state of the Union to report H.R. 3.
- **Dec 12, 2019:** The previous question was ordered pursuant to the rule.
- **Dec 12, 2019:** The House adopted the amendments en gross as agreed to by the Committee of the Whole House on the state of the Union.

- Dec 12, 2019:** Mr. Upton moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H10223)
- **Dec 12, 2019:** DEBATE - The House proceeded with 10 minutes of debate on the Upton motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to change the effective date of the Act until the Secretary of Health and Human Services certifies that the implementation of the provisions in the bill are not projected to result in fewer new drug applications with respect to unmet medical needs and life saving cures.
 - **Dec 12, 2019:** The previous question on the motion to recommit with instructions was ordered without objection.
 - **Dec 12, 2019:** On motion to recommit with instructions Failed by the Yeas and Nays: 196 - 226 (Roll no. 681).
 - **Dec 12, 2019:** Passed/agreed to in House: On passage Passed by the Yeas and Nays: 230 - 192 (Roll no. 682).
 - **Dec 12, 2019:** On passage Passed by the Yeas and Nays: 230 - 192 (Roll no. 682).
 - **Dec 12, 2019:** Motion to reconsider laid on the table Agreed to without objection.
 - **Dec 11, 2019:** Considered under the provisions of rule H. Res. 758. (consideration: CR H10096-10117)
 - **Dec 11, 2019:** The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.
 - **Dec 11, 2019:** House resolved itself into the Committee of the Whole House on the state of the Union pursuant to H. Res. 758 and Rule XVIII.
 - **Dec 11, 2019:** The Speaker designated the Honorable Donald M. Payne, Jr. to act as Chairman of the Committee.
 - **Dec 11, 2019:** GENERAL DEBATE - The Committee of the Whole proceeded with four hours of general debate on H.R. 3.
 - **Dec 11, 2019:** Mr. Scott (VA) moved that the Committee rise.
 - **Dec 11, 2019:** On motion that the Committee rise Agreed to by voice vote.
 - **Dec 11, 2019:** Committee of the Whole House on the state of the Union rises leaving H.R. 3 as unfinished business.
 - **Dec 10, 2019:** Rules Committee Resolution H. Res. 758 Reported to House. The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.
 - **Dec 9, 2019:** Reported (Amended) by the Committee on Education and Labor. H. Rept. 116-324, Part III.
 - **Dec 9, 2019:** Placed on the Union Calendar, Calendar No. 264.
 - **Dec 6, 2019:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-324, Part I.
 - **Dec 6, 2019:** Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-324, Part II.
 - **Dec 6, 2019:** House Committee on Education and Labor Granted an extension for further consideration ending not later than Dec. 9, 2019.
 - **Oct 22, 2019:** Committee Consideration and Mark-up Session Held.
 - **Oct 22, 2019:** Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 24 - 17.
 - **Oct 17, 2019:** Ordered to be Reported by the Yeas and Nays: 30 - 22.
 - **Oct 17, 2019:** Subcommittee on Health Discharged.
 - **Oct 17, 2019:** Committee Consideration and Mark-up Session Held.
 - **Oct 17, 2019:** Ordered to be Reported (Amended) by the Yeas and Nays: 27 - 21.
 - **Sep 25, 2019:** Subcommittee Hearings Held.
 - **Sep 20, 2019:** Referred to the Subcommittee on Health.
 - **Sep 19, 2019:** Introduced in House
 - **Sep 19, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 - **Sep 19, 2019:** Referred to the Subcommittee on Health.

LegiList

CONGRESS, MADE CLEAR.

Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

legilist.com

Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

legilist.com/learn

Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

legilist.com/api

Public data belongs to the public. — legilist.com